Combination therapy for effecting weight loss and treating obesity

A controlled release dosage form comprising phentermine and topiramate in amounts that in combination are effective to induce weight loss in a patient, wherein the dosage form provides for immediate release of the phentermine and delayed release of the topiramate.

A controlled release dosage form comprising 15 mg of phentermine and 100 mg of topiramate, wherein the dosage form provides for immediate release of the phentermine and delayed release of the topiramate.

A controlled release dosage form comprising 8 mg of phentermine and 50 mg of topiramate, wherein the dosage form provides for immediate release of the phentermine and delayed release of the topiramate.

A method for effecting a desired weight loss in a subject, comprising administering 15 mg of phentermine and 100 mg topiramate to said subject on a daily basis until the subject has experienced the desired weight loss.

A method for effecting a desired weight loss in a subject, comprising administering 8 mg of phentermine and 50 mg topiramate to said subject on a daily basis until the subject has experienced the desired weight loss.

A method for effecting a desired weight loss in a subject in need thereof comprising administering to said subject, on a daily basis and until the desired weight loss is achieved, a therapeutically effective amount of a sympathomimetic agent that has anorexient properties, is anorectic without undesirable side effects or loss of efficacy when combined with an anticonvulsant agent, or both, and an amount of an anticonvulsant agent selected to prevent the loss of effectiveness of the sympathomimetic agent alone.

A method for treating at least one side effect associated with obesity comprising administering to a subject, on a daily basis and until the side effect associated with obesity is effectively treated, a therapeutically effective amount of a sympathomimetic agent that has anorexient properties, is anorectic without undesirable side effects or loss of efficacy when combined with an anticonvulsant agent, or both, and an amount of an anticonvulsant agent selected to prevent the loss of effectiveness of the sympathomimetic agent alone.

A method for treating Syndrome X in a subject comprising administering to the subject, on a daily basis and until Syndrome X is effectively treated, a therapeutically effective amount of a sympathomimetic agent that has anorexient properties, is anorectic without undesirable side effects or loss of efficacy when combined with an anticonvulsant agent, or both, and an amount of an anticonvulsant agent selected to prevent the loss of effectiveness of the sympathomimetic agent alone.

A controlled release formulation comprising phentermine and topiramate, wherein oral administration of the formulation results in immediate release of the phentermine and controlled release of the topiramate, and further wherein the topiramate is present in the form of granules, delayed release granules, granules within a matrix, or a combination with a polymeric mixture.

A controlled release formulation comprising 15 mg phentermine and 100 mg topiramate, wherein oral administration of the formulation results in immediate release of the phentermine and delayed release of the topiramate, and further wherein the topiramate is present in the form of granules, delayed release granules, granules within a matrix, or a combination with a polymeric mixture.

A controlled release formulation comprising a topiramate core and a layer of phentermine such that oral administration of the formulation provides for immediate release of the phentermine and delayed or sustained release of the topiramate.

A dosage form comprising phentermine in an immediate release, readily dissolvable form and delayed release granules of topiramate.